Sichuan Getein Biotechnology Co., Ltd. announced that it expects to receive CNY 30 million in funding from Getein Biotech, Inc
February 23, 2022
Share
Sichuan Getein Biotechnology Co., Ltd. announced that it will receive CNY 30 million in an equity round of funding on February 24, 2022. The transaction will include participation from returning investor Getein Biotech, Inc. The transaction got approved by the 16th meeting of the third board of directors of the company. After the completion, the registered capital of the company will increase from CNY 30 million to CNY 60 million.
Getein Biotech Inc is a China-based company mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments. Its in vitro diagnostic reagents include Point-of-care Testing (POCT) reagents, chemiluminescence reagents, biochemical reagents, blood cell reagents, hemagglutination reagents and others. Its diagnostic instruments include immunoquantitative analyzer FIA 8000, immunoquantitative analyzer FIA 8600, fluorescence immunoquantitative analyzer Getein 1100, fluorescence immunoquantitative analyzer Getein 1180, automatic biochemical analyzer CM 400, automatic chemiluminescence analyzer MAGICL 6000 and five classification blood cell analyzer BHA-5000, among others. The Company also provides testing and agency services. The Company distributes its products within domestic market and to overseas markets.
GETEIN BIOTECH, INC 
